RxDoctor Payments Data

Moumita Naidu, MD

Cardiovascular Disease · Indianapolis, INNPI 1841619343

Payments from drug & device makers

$1,398in general payments, 2019–2025

Across 24 payments — averaging $58.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$494
  • Boehringer Ingelheim$164
  • Amgen$143
  • W. L. Gore & Associates, Inc.$135
  • Pfizer$124
  • Medtronic$105
  • plus $233 from 8 others

What the payments were for

  • Food & beverage$1,398100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,398 in reported general payments places this provider in the 35th percentile of 408 cardiovascular disease providers in Indiana.

See all cardiovascular disease providers in Indiana

Medicare billing

Part B allowed, 2024
$101,078
Medicare patients
795
Services billed
1,716

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban250$261,837
JardianceEmpagliflozin50$67,409
EntrestoSacubitril/Valsartan58$61,323
Repatha SureclickEvolocumab57$35,143
XareltoRivaroxaban25$32,301
Praluent PenAlirocumab14$11,355
Repatha SyringeEvolocumab13$7,331
Metoprolol Succinate277$2,213
Atorvastatin Calcium232$1,728
Diltiazem 24hr Er (Cd)Diltiazem Hcl22$986
Metoprolol Tartrate156$951
Losartan Potassium97$878
Amlodipine Besylate114$852
Ezetimibe88$732
Rosuvastatin Calcium80$680

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$124$261,837250 claims
Boehringer IngelheimJardiance$164$67,40950 claims
NovartisEntresto$21$61,32358 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 408 cardiovascular disease providers in Indiana.

Other cardiovascular disease in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →